Background: The aim of the study was to investigate the hypoglycemic effects of Phloridzin.
Introduction
As a complex metabolic condition, diabetes mellitus is a risk factor for coronary artery diseases that affect both individuals and society as a whole. It is estimated that in 2030, 522 million adults will be suffering from diabetes worldwide (García-Toro et al, 2016). Type-2 diabetes is generally identified by reduced insulin secretion (Hattori et al., 1985) and increased insulin resistance, which are associated with inflammation (DeFeudis, 1991). Insulin resistance, which is associated with insulin response, causes problems in the liver and adipose tissue and continues throughout the chronic inflammatory state.
Physiologically active substances in food have lesser adverse side effects, lower costs and the better health benefits of these therapies, as well as their acceptability among people. They have been developed as functional foods to prevent diabetes in conjunction with traditional antidiabetic drugs (i.e., sulfonylurea, thiazolidinedione, and glucagon-like peptide 1 analogs) (Haines et al., 2000) . Phloridzin is found in apples and apple products (Gosch et al., 2010 ; Perez-Jimenez et al., 2010). Wojdylo et al. showed that the dihydrochalcones phloridzin and phloretin 2′-xyloglucose account for 0.5-5% of the polyphenols in apple varieties (Wojdylo et al., 2008) . According to the Phenol-Explorer database (http://www.phenol-explorer.eu), phloridzin exists in apples with a mean content of 2.75 mg/100 g of fresh weight. In recent years, studies of phloridzin in diabetes have been performed in many countries (Brouwers et al., 2013; Randhawa et al., 2013) . It is suggested that phloridzin contributes to the high antioxidant activity of apples (Boyer et al., 2004; Lee et al., 2003; Wojdylo et al., 2008) . Phloridzin is of significant interest to mammalian physiologists because of its ability to block sodium-linked glucose transport and block renal re-absorption of glucose in the kidney (Ehrenkranz et al., 2005) . Thus, phloridzin is a promising food component that may prevent diabetes mellitus and other lifestyle-related diseases by its antioxidant ability or its ability to inhibit glucose absorption. Oral glucose tolerance testing was performed during the last week of treatment. After a 12-hour fasting, the animals were orally gavaged with 2 g/kg body weight of glucose dissolved in water (40%, wt/vol). Blood glucose levels were measured at 0 and 120 min by glucose oxidase method according to the instruction.
Assay of FBG, FINS, Serum Leptin, Adiponectin, and CRP
Blood glucose concentration was determined with a handheld glucometer (Ascensia Contour glucometer, Bayer) (Woods et al., 2003) . Plasma insulin concentration was measured by enzyme-linked immunosorbent assay kit (Seikagaku Corp, Kanagawa, Japan) (Liversy et al., 1980) . Serum leptin, adiponectin, and CRP were detected by ELISA kits.
Statistical Analysis
All experiments and analyses were performed at least in triplicate. Results are expressed as means ± SE. Statistical analyses were performed using the Student′s t-test. Values of P < 0.05 were considered to be statistically significant. 
Results
Food-intake in diabetes model group was significantly lower than that in normal group. Both Rosiglitazone and Phloridzin treatment didn't obviously affect the food intake relative to diabetes model control; Water-intake in diabetes model group was significantly lower than that in normal group. Both Rosiglitazone and Phloridzin treatment obviously decreased the water intake relative to diabetes model control; Body weight in diabetes model control group was significantly increased compared to normal control group. Both Rosiglitazone and Phloridzin treatment obviously decreased the body weight of diabetes mice ( Table 1) .
The results of the OGTT at the end of the experiment (week 10) are shown in Fig. 1A and B. Glucose tolerances were impaired at 10 weeks in the diabetes model control, rosiglitazone and phloridzin treatment groups, while the AUCglucose values in the rosiglitazone and phloridzin treatment groups were effectively lower than that in the diabetes model control group (p < 0.01). In the diabetic control group, FBG, FINS, HOME-IR, serum leptin, and CRP levels significantly (p<0.01) increased within 12 weeks compared to normal control. However, serum adiponectin in the diabetic control mice decreased significantly within 12 weeks (p<0.01, Table 2 ). Phloridzin (60 mg/kg bw) treatment significantly (p<0.01) decreased FBG, FINS, HOME-IR, serum leptin, and CRP levels, increased serum adiponectin in Phloridzin treatment group compared to diabetic control mice (Table 2 ). In the positive control group, rosiglitazone (15 mg/kg bw) led to a significant decrease in FBG, FINS, HOME-IR, serum leptin, and CRP levels and increase in serum adiponectin within 12 weeks compared to the diabetic control group (p<0.05, p<0.01). In the diabetic control group, the hepatic PEPCK, G-6-Pase activities increased significantly during the experiment compared to the normal control group (p<0.01). Hepatic GK activity and glycogen level decreased significantly during the experiment in the diabetic control group (p<0.01). Phloridzin (60 mg/kg bw) significantly inhibited the tendency of hepatic PEPCK, G-6-Pase activities to increase and of hepatic GK activity and glycogen level to decrease in diabetic mice during the entire experiment 
Discussion
We found that treating mice with high-fat diet-induced T2D with 60 mg/kg/day of phloridzin significantly reduced their water-intake and body weight, but didn't affect food-intake. Additional oral glucose tolerance data indicated that phloridzin significantly increased plasma glucose tolerance, including the altered pattern and the reduced averaged glucose levels of the AUC for diabetic mice at the end of our study. Impaired OGTT is an important standard for type 2 diabetes, which has often been used to derive estimates of the relative roles of insulin secretion and insulin resistance in population studies of glucose tolerance (Guo et al., 2015) . A diet containing 0.5% or 1% phloridzin significantly reduced the blood glucose levels in BALB/c mice after 7 days of feeding. A 0.5% phloridzin diet significantly suppressed the blood glucose levels in STZ-induced diabetic mice most likely by High concentrations of plasma glucose and insulin levels were maintained by feeding high-fat diet without phloridzin to KKAy mice for 10 weeks. Hyperglycemia is associated with the consequences of hyperinsulinemia, insulin resistance, and glucose intolerance in diabetes (Lamming et al., 2013) . During the feeding period, we confirmed that hyperinsulinemia and insulin resistance worsened in mice fed the high-fat diet. However, the elevation of FBG and fasting insulin levels in diabetic mice was markedly suppressed by the administration of phloridzin. One possible reason for this effect is that phloridzin prevents chronic elevation of postprandial blood glucose and insulin levels.
Leptin, another adipokine of 16 kDa, is located on 7q31.3 chromosomal region and is a product of obesity gene (Zhang et al., 1994) . Hyperleptinemia, represents a condition of elevated leptin levels and is commonly accompanied by components of metabolic syndrome, that is: hyperlipidemia, hypertension, increased adipose tissue, and insulin resistance (Leyva et al., 1998) . Lemieux et al (2001) reported relationships between blood levels of hs-CRP and adiponectin with obesity indices and metabolic markers in populations consisting of both obese and lean subjects involving a wide range of weight and body mass index. In this study, phloridzin (60 mg/kg bw) treatment significantly decreased serum leptin, and CRP levels, increased serum adiponectin in phloridzin treatment group compared to diabetic control mice.
Our data show that compared to the normal control group, the diabetes control group developed noticeably greater lipid accumulation in the liver tissue and that body and liver weights in the diabetes control group were also dramatically increased compared to those of the normal control group. However, supplementation with phloridzin significantly lowered lipid accumulation in the liver and suppressed body and liver weight increases compared to those of the diabetes control group. Our data also suggests that phloridzin suppresses high-fat-diet-induced adipose tissue mass and body gain, and may inhibit lipid accumulation in adipose tissue in particular.
The liver is mainly responsible for maintaining normal concentrations of blood glucose by regulating glycolysis and gluconeogenesis (Roden & Bernroider, 2003) . In glycolysis, GK is key rate-limiting enzymes mediating glucose oxidation, which hepatic gluconeogenesis contributes to glycemic control in diabetic patients (Foretz et al., 2010) . In the present study, significant decrease in activitiess of PEPCK and G-6-Pase, which suggests attenuation of gluconeogenesis and consequent decrease in glucose-6-phosphate dephosphorylation to free glucose, were detected in DPM-treated diabetic mice. Glycogen is the primary intracellular storable form of glucose, and its levels in various tissues, especially in the liver, kidney, and skeletal muscles, directly reflect insulin activity, which in turn regulates glycogen deposition by stimulating glycogen synthase and inhibiting glycogen phosphorylase (Palsamy & Subramanian, 2009 ). Reinstatement of glycogen levels in diabetic mice with phloridzin treatment suggests that phloridzin facilitates conversion of glucose-6-phosphate to glycogen, which then results in attenuation of hepatic glucose output.
In conclusion, our results showed that phloridzin supplementation reduced blood glucose, serum leptin, CRP levels, increased serum adiponectin level, improved insulin resistance in type 2 diabetic patients. In addition, phloridzin supplementation increased hepatic GK, decreased hepatic PEPCK, G-6-Pase activities. This suggested that phloridzin promoted glycolytic pathway, decreased gluconeogenic pathway and increased hepatic glycogen synthase in type 2 diabetic patients.
